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Abstract    Medium molecular weight conjugates of glycol-chitosan have been 
prepared, linked by an amide bond to paramagnetic Gd(III), Ho(III) and Dy(III) 
macrocyclic complexes in which a trifluoromethyl reporter group is located 6.5Å 
from the paramagnetic centre. The faster relaxation of the observed nucleus allows 
modified pulse sequences to be used with shorter acquisition times. The polydisperse 
materials have been characterized by gel permeation chromatography, revealing an 
average MW of the order of 13,800 (Gd), 14,600 (Dy) and 16,200 (Ho), consistent 
with the presence of 8.5, 9.5 and 13 complexes respectively. The Gd conjugate was 
prepared for both a q = 1 monoamide-tricarboxylate conjugate (r1p 11.2 mM
-1
s
-1
, 
310K, 1.4T) and a q = 0 triphosphinate system and conventional contrast enhanced 
proton MRI studies at 7T undertaken in mice bearing an HT-29 or an HCT-116 
colorectal tumour xenograft (17mol/kg). Enhanced contrast was observed following 
injection in the tail vein in tumour tissue, with uptake also evident in the liver and 
kidney with a tumour/liver ratio of 2:1 at 13 minutes, and large amounts in the kidney 
and bladder consistent with predominant renal clearance.  Parallel experiments 
observing the 
19
F resonance in the Ho conjugate complex using a surface coil did not 
succeed owing to its high R2 value (750Hz, 7T). However, the fluorine signal in the 
Dy triphosphinate chitosan conjugate (R1/R2 = 0.6 and R1 = 145 Hz (7T)) was sharper 
and could be observed in vivo at -65.7 ppm, following intravenous tail vein injection 
of a dose of 34 mol/kg.  
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Abbreviations 
NMM  N-methyl morpholine 
TBTU  Tetramethyluronium tetrafluoroborate 
GPC  gel permeation chromatography 
DO3A  1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane 
PDI  polydispersity index 
MRI  magnetic resonance imaging 
MRSI  magnetic resonance spectroscopic imaging 
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Introduction 
 Fluorine magnetic resonance imaging has been promoted as an alternative to 
proton MRI or MRSI, due to the 100% isotopic abundance of the 
19
F nucleus, the high 
NMR sensitivity and near zero background signal. [1,2] Over the past 20 years, 
notwithstanding the use of dedicated imaging coils, such work has been limited to 
observation of probes with high spin-density, e.g. locally injected perfluoralkyl and 
perfluoro-crown ether suspensions. Overall, limited impact has occurred and only 
sporadic applications reported. [3] Over the past 5 years, we have shown that 
improvements in sensitivity of between 10 and 25-fold can be gained in 
19
F MR 
imaging, by placing a reporter trifluoromethyl group between 4.5 and 7Å from a 
paramagnetic centre, such as a lanthanide ion (in particular: the faster relaxing and 
shifting ions: Dy, Tb Ho, Er and Tm). [4,5] Too close and line-broadening is very 
severe; too distant and the relaxation rate enhancement is very small. An alternative 
approach has been suggested using a proximate Fe
3+
 or Mn
2+
 centre, in the context of 
monitoring enzymatic transformations by 
19
F NMR, although rate enhancements were 
rather lower than ideal in the cases cited. [6]  For rates of longitudinal relaxation of 
between 50 and 250 Hz, much shorter acquisition times can be used, including the use 
of a ‘zero-echo time’ imaging pulse sequence. [7] These approaches are generally 
applicable to any spin ½ nucleus, and require that the R1/R2 ratio is as close as 
possible to unity and that R2 is preferably no greater than 300 to 500 Hz. Otherwise, 
concomitant broadening of the signal inhibits observation in spectroscopy. In 
imaging, if R2 becomes large, “T2 losses” occur during acquisition, associated with the 
longer RF pulse required and the spatial encoding process, limiting any intrinsic 
sensitivity gains.   
 A further aspect of this approach to more practicable 
19
F imaging is that the 
spin density should be maximised within the region of interest that is observed. The 
use of low MW fluorine labelled lanthanide complexes per se is constrained by their 
rapid rates of clearance, following intravenous introduction into the body. With this in 
mind, we have set out to study medium MW polydisperse conjugates, in which about 
30 fluorine nuclei (i.e. 10 CF3 groups, on average) are linked to a biocompatible 
vector. Such an approach has one main benefit in that the material will tend to clear 
more slowly from the body, as diffusion into the extravascular space is retarded. Such 
behaviour will increase the opportunities for 
19
F imaging of probe location, prior to 
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excretion. The use of a conjugate that is readily metabolised by the action of natural 
glycosidase enzymes was also considered to offer advantages in ensuring longer term 
whole body clearance, as the lower molecular weight monomeric complexes are 
normally expected to clear rapidly via the renal or biliary routes.    
 In this work, monomeric CF3 labelled lanthanide complexes have been used as 
they are kinetically inert with respect to premature dissociation of the metal ion in 
vivo. [8,9] Thus, complexes of monoamide-tricarboxylate and triphosphinate 
derivatives of 1,4,17,10-tetraazacyclododecane have been used, as they have been 
shown to be resistant to acid catalysed dissociation pathways. [10] Furthermore, the 
CF3 group is engineered to be about 6 to 6.5Å from the paramagnetic centre. At this 
distance and at a field of 7 T, this makes the complexes of Tb, Dy and Ho rational 
choices for exploration, as they possess R1 values in the range 50-150 Hz, under these 
conditions. [4c, 11] 
 Chitosan is a linear polysaccharide composed of randomly distributed -(1-4)-
linked D-glucosamine and N-acetyl-D-glucosamine moieties. Importantly, it is non-
toxic, biodegradable and is tolerated well in vivo. [12] It is produced via the de-
acetylation of chitin and is a cheap and readily available high molecular weight vector 
for bio-conjugation work. The aqueous solubility is enhanced in the simple derivative, 
glycol-chitosan; this is commercially available. The material is polydisperse and, in 
this work, it was hydrolysed by acid digestion for 24h. [12-14] Such treatment 
generates a precursor in which the amide bonds are cleaved and the polysaccharide 
partially hydrolysed, to yield a material with an average of 35 monosaccharide units, 
in which the primary amine groups are amenable for conjugation.  Thus, the 
conjugates [Ln.L
1
-chitosan] and [Ln.L
3
-chitosan] were studied, with [Ln.L
2
] 
prepared as a control (Scheme 1). The corresponding Gd complexes serve as proton 
MRI contrast agents, catalyzing the rate of relaxation of the bulk water signal which is 
in proximity. Hence, proton MRI studies were undertaken first to define the location 
of the conjugate, and 
19
F imaging studies attempted thereafter, aided by knowledge of 
the tissue distribution of the conjugate.  
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 [Ho.L
1
-chitosan(H2O)]            [Ho.L
2
(H2O)]                     [Dy.L
3
-chitosan] 
 
 Scheme 1  Structures of complexes and conjugates studied 
 
 
Materials and Methods 
 
Gel Permeation Chromatography 
 
Gel permeation chromatography (GPC) was undertaken at Smithers Rapra UK, using 
a Viscotek Model 301 TDA instrument with associated pump, autosampler, and 
refractive index detector (with differential pressure and light scattering). Agilent 
PLaquagel-OH Guard plus 2 x PLaquagel-OH Mixed-M, 30 cm, 8 µm columns were 
used with an eluent composed of 0.5 M NaNO3, 0.01 M NaH2PO4 at pH 2 at a flow 
rate of 1.0 mL/min at 30°C.  The GPC system was calibrated using Pullulan 
polysaccharides and the data analysed using Malvern/Viscotek ‘OmniSec’ software. 
 
Mass Spectrometry 
 
Both standard and high resolution electrospray mass spectrometry were recorded on a 
Thermo-Finnigan LTQ FT instrument, operating in positive or negative ion mode as 
stated, with MeOH as the carrier solvent.  MALDI mass spectra were recorded on an 
Applied Biosystems Voyager-DE STR instrument with MeOH as the carrier solvent.  
LC-MS analyses were performed on a Waters system comprising a 3100 Mass 
Detector and a 2998 Photodiode array detector. 
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NMR Spectroscopy 
 
1
H, 
13
C, 
19
F, and 
31
P NMR spectra were recorded in commercially available 
deuterated solvents on a Varian Mecury-200 (
1
H at 199.975 MHz, 
13
C at 50.289 MHz, 
19
F at 188.179 MHz, 
31
P at 80.985 MHz), Varian Mercury-400 (
1
H at 399.960 MHz, 
13
C at 100.572 MHz, 
19
F at 376.338 MHz, 
31
P at 161.943 MHz), Bruker Avance-400 
(
1
H at 400.052 MHz, 
13
C at 100.603 MHz, 
19
F at 376.423 MHz, 
31
P at 161.980 MHz), 
Varian Inova-500 (
1
H at 499.722 MHz, 
13
C at 125.671 MHz, 
19
F at 470.253 MHz, 
31
P 
at 202.375 MHz), Varian VNMRS-600 (
1
H at 599.944 MHZ, 
19
F at 564.511, 
31
P at 
242.862 MHz), or Varian VNMRS-700 (
1
H at 699.731 MHz, 
13
C at 175.948 MHz, 
19
F 
at 658.405 MHz,
 31
P at 283.256 MHz) spectrometer.  All chemical shifts are given in 
ppm and coupling constants are in Hz.  Longitudinal relaxation times (T1) were 
measured in dilute D2O solutions at 295 K using the inversion-recovery technique.  
For 
19
F, the relaxation data were measured without proton decoupling and the 
chemical shifts are reported relative to fluorotrichloromethane. 
 
1
H and 
17
O Relaxometry 
 
The proton 1/T1 Nuclear Magnetic Relaxation Dispersion (NMRD) profiles were 
measured on a fast field-cycling Stelar SmartTracer relaxometer (Mede, Pv, Italy) 
over a continuum of magnetic field strengths from 0.00024 to 0.25 T (corresponding 
to 0.01-10 MHz proton Larmor frequencies). The relaxometer operates under 
computer control with an absolute uncertainty in 1/T1 of ± 1%. The temperature was 
controlled with a Stelar VTC-91 airflow heater equipped with a calibrated copper–
constantan thermocouple (uncertainty of ±0.1 K). Additional data points in the range 
15-70 MHz were obtained on a Stelar Relaxometer equipped with a Bruker WP80 
NMR electromagnet adapted to variable-field measurements (15-80 MHz proton 
Larmor frequency). For these 
1
H data ca. 0.5-1.2 mM solutions of the Gd(III) 
complexes in non-deuterated water at neutral pH were utilized. The exact complex 
concentration was determined by the bulk magnetic susceptibility shift (BMS) method 
on a Bruker Avance III operating at 11.7 T. Other relaxation measurements were 
made at 1.4 T using a Bruker Minispec mQ 60  relaxometer, operating at 310K.  
17
O NMR measurements were recorded on a Bruker Avance III spectrometer (11.7 T) 
equipped with a 5 mm probe and standard temperature control unit. An 8 mM 
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aqueous solution of the complex containing 2.0% of the 
17
O isotope (Cambridge 
Isotope) was used. The observed transverse relaxation rates were calculated from the 
signal width at half-height. 
 
MRI studies 
 
Imaging studies were carried out using a 7 T Varian Unity Inova microimaging/pre-
clinical system equipped with broadband capability and actively shielded gradients.  
For the 
19
F MRI studies, a purpose built four turn solenoid coil (20 mm diameter, 20 
mm coil length) was used for in vitro experiments and a 
19
F-tuned square surface coil 
(30 mm, m2m Imaging Corp.) was used for in vivo experiments.  For the 
1
H MRI 
studies, in vitro experiments were performed with a 30 mm i.d. birdcage volume coil 
(Rapid Biomedical) and in vivo experiments were performed with a 39 mm i.d. 
birdcage volume coil.  All coils were used for both signal excitation and reception. 
 
For phantom studies, dilute aqueous samples (2-5 mM) were placed in Eppendorf 
tubes or cut down (2-3 cm) NMR tubes and positioned on the axis of the coil.  For in 
vivo studies, nude mice bearing a HT29 colorectal tumour xenograft were 
anaesthetised with oxygen/1-2 % isofluorane (for the 
1
H MRI studies) or with a 
mixture of ketamine (0.75 mg/kg) and medetomidine (0.5-1.0 mg/kg) (for the 
19
F 
MRI studies).  Complexes were administered intravenously as saline solutions via the 
tail vein, with doses typically 0.03 mmol/kg. 
 
Ligand synthesis and general methods  
 
See the ESI for additional synthesis and characterisation details. 
 
Dialysis was performed with Dialysis Tubing Cellulose Membrane MWCO 550 D 
(Sigma Aldrich), Spectra/Por Dialysis Membrane MWCO 1,000 D (Spectrum 
Laboratories, Inc), or Float-A-Lyzer G2 filters MWCO 5,000 D (Spectrum 
Laboratories, Inc).  All tubing was washed thoroughly with H2O, as per 
manufacturer’s advice.  After addition of the complex to the tubing, the ends of the 
tubing were secured (clamps for the membranes, provided screw top for the filters) 
and the ensemble submerged in stirring H2O (ca. 500 mL).  The bulk H2O was 
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exchanged 4 times over a 72 h period, to ensure a positive dialysis gradient was 
maintained.  Filtering of the tubing contents and lyophilisation yielded the desired 
product. 
 
Glycol chitosan was purchased from Sigma and purified by dialysis before use. After 
purification, the sample had a molecular weight of about 195,000 D as revealed by 
GPC analysis; its solubilisation in water required sonication over a period of two 
hours. The sample was modified to prepare a lower molecular weight polymer, by 
acidic digestion with 4M HCl at 50°C over 24 hours. After dialysis purification, the 
sample possessed an average MW of 6,590 D (vide infra) and exhibited higher water 
solubility compared to the parent system. 
 
10-[((2-4-Ethoxycarbonyl-2-(trifluoromethyl)phenylamino)-2-oxoethyl]-1,4,7-
tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane , 1 
 
 
 
To a solution of 1,4,7-tris(tert-butoxycarbonylmethyl)-1,4,7,10-
tetraazacyclododecane (500 mg, 0.97 mmol) and 2-chloro-N-(4-(ethoxycarbonyl)-2-
trifluoromethylphenyl)-ethanamide (331 mg, 1.07 mmol) in dry CH3CN (20 ml) 
under argon, was added K2CO3 (161 mg, 1.17 mmol) and KI (5 mg, cat.). The mixture 
was boiled under reflux for 24 h. After filtration, the residue was washed with CH2Cl2 
(2 x 30 ml) and solvent removed under reduced pressure to yield a pale brown oil that 
was purified by column chromatography over silica gel (CH2Cl2 to 
CH2Cl2/10%EtOH). The resultant oil was purified by crystallization from hot diethyl 
ether yielding a white powder (597 mg, 78%), m.p. 185-186°C. Rf = 0.6 (silica, 
DCM/5%EtOH); 
1
H NMR (500 MHz, CDCl3):  1.26, 1.37 (27H, br, s, CH3), 1.33 
(3H, t, J = 7.0 Hz, CH2CH3), 1.90-3.80 (24H, br, CH2 ring and CH2CO), 4.33 (2H, q, 
J = 7.0 Hz, CH2CH3), 7.76 (1H, d, J = 8.5 Hz, aromatic H
6
), 8.01 (1H, dd, J = 8.5, 1.5 
Hz, aromatic H
5
), 8.20 (1H, d, J = 1.5 Hz, aromatic H
3
), 9.48 (1H, br, s, NH); 
13
C 
N N
NN
O
O
OO
O
O
H
N
O
F3C
O
O
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NMR (125.7 MHz, CDCl3):  14.49 (CH2CH3), 27.99, 28.07 (CH3), 48.52, 52.63 (br, 
CH2 ring), 55.74, 55.82, 57.01 (CH2CO), 61.64 (CH2CH3), 82.07 (C-CH3), 123.35 (q, 
1
JCF = 274 Hz, CF3), 124.91 (q, 
2
JCF = 32 Hz, aromatic C
2
-CF3), 127.83 (aromatic C
4
), 
128.05 (q, 
3
JCF = 5 Hz, aromatic C
3
), 128.29 (aromatic C
6
), 133.23 (aromatic C
5
), 
139.60 (aromatic C
1
), 165.26 (COOEt), 172.53, 172.63, 172.75 (C=O); 
19
F NMR (188 
MHz, CDCl3):  -60.51 (CF3); ESI/MS
+
 m/z 810.4 [M + Na]
+
; MS Calcd for 
C38H60N5O9F3Na 810.4235. Found 810.4224.  
The structure of the sodium complex of 1 was confirmed by single crystal X-ray 
diffraction study of the NaBr adduct, CCDC 945380. The crystal grown from diethyl 
ether was mounted in inert oil and transferred to the cold gas stream of the 
diffractometer.  
  
 Figure 1 View of the sodium complex of the triester intermediate, 1, showing 
the position of the CF3 group with respect to the bound metal ion.  
 
 Crystal data: [C38H60N5O9F3Na]
+
Br
–
·½ Et2O, M =927.87, a = 27.177(1) Å, c = 
12.4222(4) Å, V = 9175.0(6) Å
3
, T = 120(2), tetragonal space group P4/n (no. 85), Z = 
8, μ(Mo-Kα) = 0.975, 119016 reflections measured, 13394 unique (Rint = 0.088), final 
R1= 0.037 [I≥2(I)], wR2 = 0.101 (all data).  The CF3 group is disordered, by libration 
about the C(arene) and one of the fluorine atoms, between two alternative orientations 
with occupancies of 0.8 and 0.2, (Figure 1). The shortest intramolecular F…Na 
distances for these sites are 6.054(2) and 6.14(2) Å. Given that the ionic radius for 
sodium in 8–coordination is 1.32 Å (vs 1.21 Å for Ho3+), the slightly shorter distances 
here are in line with the measurements estimated by NMR analysis of the variation of 
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the 19-F relaxation rate with field, that gave the separation of the CF3 group from the 
lanthanide ion  as 6.3 (±0.2)Å. [4c]  
 
 
Preparation of partially hydrolysed glycol chitosan (MW~6,590)  
 
 
 
Glycol chitosan (1 g, Sigma) was dissolved in a solution of hydrochloric acid  (75 ml, 
4M) and any insoluble material was manually removed from the solution. The 
solution was left stirring at 50˚C for 24 h, and then dialysed (cut off 12,000D) against 
Purite water until the pH of the tube contents reached neutrality (2 days). 
Lyophilisation yielded a light off-white powder (560 mg). Anal Found C, 37.84; H, 
6.92; N, 5.57%.  For GPC analysis, see Table 1.     
   
[Ho.L
1
(H2O)-chitosan] conjugate 
 
 
 
To a stirred suspension of [Ho.L
1
(H2O)] (260 mg, 345 mmol) in dry DMF (2.2 ml) 
under argon was added N-methylmorpholine (57 ml, 518.0 mmol) and finally TBTU 
(166 mg, 518.0 mmol). The solution was stirred for 30 min at room temperature, and 
an aqueous solution of glycol chitosan (MW~6,590) (40 mg in 0.4 ml of water) was 
added dropwise. The mixture was left stirring overnight at 40˚C. The crude was 
diluted with water and dialysed against Purite water over 2 days (cut off 1,000D). The 
solution was lyophilised to yield a light brown solid. 
19
F NMR (376.3 MHz, D2O):  -
HO
O
HO
NH2
O
OCH2CH2OH
O
HO
NH2
OH
OCH2CH2OH
x z
O
HO HO
NH2
O
OCH2CH2OH
O
HO
NH
OH
OCH2CH2OH
x y
N
N
N
N
O
O
O
O
O
O
HN
O
F3C
Ho
OH2
O
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56.8 (CF3, 1/2 = 257 Hz); Anal:  Found C, 37.65; H, 4.93; N, 7.53, Ho = 13.0 %.  For 
GPC analysis, see Table 1.    
 
Glycol chitosan Gd complex conjugate  
Prepared as described for the holmium analogue; Anal Found C, 34.84; H, 4.64; N, 
6.98, Gd = 12.9%.  r1p =  14.9 mM
-1
s
-1
 (310K, 20MHz). For GPC analysis: Table 1.  
 
 
 
Glycol chitosan Dy complex conjugate,  [Dy.L
3
-chitosan] 
 
 
 
The complex [Dy.L
3
] (157 mg, 0.184 mmol) was dissolved in anhydrous DMF (2 
mL) to which NMM (30 µL, 0.276 mmol) and TBTU (89 mg, 0.276 mmol) were 
added.  The mixture was stirred at rt for 30 min under argon, before glycol chitosan 
(20 mg, MW ≈ 6500 D) dissolved in H2O (0.2 mL) was added.  The mixture was left 
stirring at 40°C for a further 18 h, before the solution was diluted with H2O (10 mL) 
and dialysed against Purite water for 48 h (1000 MW cut-off), with the bulk solvent 
water refreshed periodically.  The solvent was removed under reduced pressure, 
before the residue dissolved in H2O and dialysed for a second time (5000 MW 
cut-off).  The solution was lyophilised to yield a white solid (48 mg).  
19
F NMR (376 
MHz, D2O, pD 6.5): δ = -65.7; Mean Mw = 14,600 D by GPC analysis, (Table 1). 
Found: Dy =  10.6 %.  
 
 The analogous [Gd.L
3
-chitosan] conjugate was made by a parallel method. Found: 
Gd = 9.7%. r1p = 12.4 mM
-1
s
-1
 (310K, 60 MHz). The relaxivity of the complex did not 
change over the pH range 6 to 7.4, but at higher pH values it increased, reaching a 
O
HO HO
NH2
O
OCH2CH2OH
O
HO
NH
O
OCH2CH2OH
H
x y
HN
F3C
O
O
N
N
N
N
P
O
O
P
O
O
P
O
O
Dy
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value of 27.2 mM
-1
s
-1
 (pH 11). An apparent pKa of 9.5 (±0.2) can be tentatively 
associated with the changes in hydration associated with amide deprotonation and the 
deprotonation of residual NH3 protons on the chitosan.   
 
Table 1   Gel permeation chromatography (GPC) data for partially hydrolysed 
glycol chitosan precursor and its conjugates  
 
Sample Mw 
a 
Mn 
b 
PDI 
c 
Glycol- 
chitosan    6,590   2,250 2.9 
[Ho.L
1
] 
conjugate   16,200   4,500 3.6 
[Gd.L
1
] 
conjugate 
[Gd.L
3
] 
conjugate 
[Dy.L
3
] 
conjugate 
  15,950 
 13,800 
 
 
14,600 
  4,155 
 6,890 
 
 
7,620 
3.8 
2.0 
 
 
1.9 
Mean values obtained from two successive runs. 
a
 calculated molecular weight averages 
expressed as the pullulan polysaccaride equivalent molecular weights; 
b
 number average 
molecular weights; 
c
 polydispersity (Mw/Mn). 
 
 
 
Results and Discussion 
Complex and conjugate synthesis 
 
The syntheses of the ligands L
1
 and L
3
 have been detailed recently [5a,5b]. The 
lanthanide(III) complexes derived therefrom  were purified by preparative scale 
reverse-phase HPLC. High resolution accurate mass spectrometry confirmed the 
constitution of the complex, with experimental isotope patterns showing good 
correlation to those calculated.  The 
19
 F NMR spectrum (D2O, 295K 9.4T) revealed 
the presence of one major (87%) and six minor species in solution, consistent with the 
J Biol Inorg Chem 13 
formation of one predominant stereoisomer, amongst the 32 NMR distinguishable 
isomers that are theoretically possible in this system  [10]. 
A representative synthesis of the conjugate, [Dy.L
3
-chitosan] is outlined in Scheme 
2.  The carboxylic acid group of [Dy.L
3
] was converted to an active ester, by reacting 
with o-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) 
and 4-methylmorpholine (NMM) in DMF.  After stirring for 1 h, to allow formation 
of the active ester, a concentrated aqueous solution of partially hydrolysed glycol 
chitosan (average MW 6,590 D) was added and the mixture stirred for a further 36 h.  
Purification of the conjugate was achieved by extensive dialysis to remove unreacted 
coupling reagents and excess complex. 
 
 
Scheme 2 Synthesis of the chitosan conjugate complex, [Dy.L
3
-chitosan]. 
 
To determine the average size and mean number of complexes conjugated to chitosan, 
the complex was analyzed by aqueous gel permeation chromatography (GPC, Table 1 
above). By comparing the molecular weights of the unreacted complex and glycol 
chitosan with that of [Dy.L
3
-chitosan], it was calculated that there are around 8.5 
complexes bound to each molecule of glycol chitosan.  As glycol chitosan is a 
polydisperse material, such values are averages for the whole system.  Low solubility 
in water had been observed in preliminary work with chitosan-conjugates derived 
from a higher MW precursor, but no solubility issues were seen with the conjugate 
reported here, at the concentrations employed (up to 10 mM). 
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Figure  2 
19
F NMR spectrum of [Dy.L
3
-chitosan] (D2O, 9.4 T, pD 7.4, 0.1 M 
NaCl, 298 K), showing the presence of one major (86%) and six minor 
isomeric species in solution. 
 
The 
19
F NMR spectrum of [Dy.L
3
-chitosan] displayed one principal resonance (86 
%), indicating equivalence of each complex in the conjugated adduct (Fig. 2).  The 
occurrence of one major resonance is required for in vivo applications to ensure that 
signal intensity is maximised. Relaxation rates were measured at 4.7 and 9.4 T, (Table 
2), along with the data for the parent complex, [Dy.L
3
], and [Ho.L
1
(H2O)chitosan].  
 
Table 2 
19
F NMR longitudinal and transverse relaxation rates at two magnetic 
fields (4.7 and 9.4 T, 295K, D2O) for Dy and Ho complexes. 
 
Complex δF / ppm 4.7 T 9.4 T 
 R1 / Hz R2 / Hz  R1 / Hz R2 / Hz 
(a)
 
[Dy.L
3
]
  
-64.5 110 217 186 440 
[Dy.L
3
-chitosan]  -65.7 108 176 183 367 
[Ho.L
1
)-chitosan]  
[Ho.L
2
(H2O)]
 
-56.8 
-56.8 
 
56 
59 
 
741 
173 
100 
123 
807 
292 
(a) R2 values were estimated as (πω1/2) for a Lorentzian line fit.  
 
There is a substantial improvement in relaxation rates for the phosphinate conjugate, 
[Dy.L
3
-chitosan], over the carboxylate based system, [Ho.L
1
-chitosan]. Such a 
difference is most likely due to a longer electronic relaxation time T1e, in the former 
series, associated with a bigger static and transient ligand field [11]. The longitudinal 
relaxation rate, R1, is almost twice as large for the dysprosium system, coupled with a 
sizeable reduction in the transverse relaxation rate, R2, calculated from the linewidth.  
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Each of these factors will serve to improve signal intensity and the combination of the 
improvement in both relaxation rates suggested considerable scope for acquisition of 
a 
19
F MR image with [Dy.L
3
-chitosan].  
 
Proton relaxation studies with the Gd complex conjugate of [Gd.L
1
(H2O)] 
 
The relaxivities of a diluted solution of the Gd-chitosan conjugate in water and of the 
monomeric Gd complexes, [GdL
1
(H2O)], were measured at 60 MHz and 37°C. The 
parent complex had a value of 4.62 mM
-1
s
-1
, which is typical of such a mono-aqua 
[Gd.DO3A-monoamide] complex. [15] In the glycol chitosan conjugate, [Gd.L1-
chitosan], the relaxivity was 11.2 mM
-1
s
-1
. Such an enhancement is associated with 
slower rotation of the Gd complex, increasing the value of the rotational correlation 
time R, leading to a higher relaxivity.  [15] In theory, the increased viscosity of the 
solution, due to the presence of the dissolved polymer, may also be responsible for an 
increased relaxivity as molecular tumbling is slowed down.  To confirm whether the 
higher relaxivity value of the conjugate was related to a change in solution viscosity 
or to the presence of the covalently linked macromolecule, a control experiment was 
performed. A solution containing the Gd complex and the precursor 6600 MW glycol 
chitosan was prepared and its relaxivity measured at 60 MHz at 37°C. The value 
obtained was 4.79 mM
-1
s
-1
, which is very similar to that of the parent complex. Such 
behaviour shows that the observed increased relaxivity is caused by the presence in 
solution of the covalently bonded conjugate. 
 The Gd conjugate can be employed as a conventional contrast agent in proton 
MRI by virtue of its ability to enhance the rate of relaxation of the bulk water protons. 
The relaxation behaviour was assessed and compared to the behaviour of the parent 
Gd complex. Variable temperature 
17
O NMR measurements for [Gd.L
1
(H2O)] were 
performed in 
17
O-enriched water (Fig. 3) and the data analyzed using the standard 
Swift-Connick methodology [16] to obtain an estimate of the water exchange lifetime 
M. The analysis gave a M value of 0.92 s at 298 K, similar to related mono-amide 
derivatives based on [Gd-DO3A] [15]  
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Figure 3  Proton relaxivity study for [Gd.L
1
(H2O)] showing the fit 
(line) to the measured data: (top left) 
17
O R2 vs temperature profile 
measured at 11.7 T (500 MHz); (top right) relaxivity vs temperature 
profile measured at 20 MHz and pH 7.2; (bottom) 1/T1 NMRD profiles at 
298K (filled circles) and 310K (open circles).  
 
The relaxivity profiles as a function of temperature and magnetic field allowed 
information to be deduced on the water exchange rate and various associated 
parameters used in the Solomon-Bloembergen-Morgan equations. Fitting was 
undertaken assuming the presence of one coordinated water molecule (q = 1), at a 
distance of 3.0 Å from the metal ion (rGdH) and fixing the values for the distance of 
closest approach to the paramagnetic centre of the outer sphere solvent molecules (a = 
4.0 Å) and for their diffusion coefficient (D = 2.24 and 3.10 cm
2
 s
-1
, at 298 and 310K 
respectively). The values of the main parameters that describe the proton relaxation 
behaviour of the complex are reported (Table 3) and are consistent with those 
expected for such low molecular weight mono-aqua complexes, with an additional 
contribution modelled as two more distant (q’’) water molecules, located on average 
4.4 Å from Gd. It is worth noting that this analysis is not entirely rigorous and 
provides only an estimate of the magnitude of the contribution of second sphere 
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0
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solvent molecules to the overall relaxivity of the complexes. Clearly, a number of 
water molecules at different distances from the metal ion and with different lifetimes 
all contribute together to the observed relaxivity. The contribution of this mechanism 
is equivalent to that of two water molecules at a distance of 4.4 Å from Gd or to that 
of a single molecule localized at about 3.9 Å [15]    
 
Table 3   Relaxation data for [GdL
1
(H2O)] 
 
Parameter 
a 
298 K 
r1p (mM
-1 
s
-1
) 5.2 
M (s) 0.92 
R (ps) 83 
V  (ps) 16 
2 (s-2  1019) 8.8 
q’’ 2 
r’’ (Å) 4.4 
 a
 r1p is the proton relaxivity; M is the water exchange lifetime; R is the 
rotational correlation time; V  is the correlation time for the ZFS 
modulation; 2 is the mean-square zero field splitting energy; q is the 
number of inner sphere water molecules; q’’ is the number of second 
sphere water molecules and r’’ their distance from Gd. 
 
For the Gd-conjugate, the relaxivity behaviour as a function of temperature and 
magnetic field were also measured (Fig. 4). In the case of macromolecular conjugates, 
the analysis of NMRD profiles requires a different approach, since the presence of a 
relatively fast local rotation of the complex, compared to the slow motion of the 
macromolecule, needs to be considered. This is possible by incorporating the 
description of the rotational dynamics according to the ‘model-free’ Lipari–Szabo 
approach into the Solomon-Bloembergen-Morgan equations for the inner sphere 
relaxation mechanism. [17,18] This model allows the contribution of the global 
rotation of the whole paramagnetic system (RG) to be separated from the contribution 
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of a faster local motion (RL) associated with free rotation of the complex via the 
pendant arm.  
                              
  
 
Figure 4 Proton relaxivity studies for [Gd.L
1
(H2O)-chitosan]: (right) relaxivity vs 
temperature profile measured at 20 MHz;  (left) 1/T1 NMRD profiles at 298K (filled 
circles) and 310 K (open circles); (centre): higher frequency NMRD profiles analyzed 
with the Lipari-Szabo model  [17,18] 
 
The correlation of the two types of motions is described by the parameter S
2
 whose 
value ranges between zero (completely independent motion) and one (totally 
correlated motion). The fitting of the NMRD profiles with the Lipari-Szabo model is 
also shown (Fig. 4 centre) and the resulting best-fit parameters reported in Table 4. 
For the macromolecular conjugates, only the high field region was analyzed because 
of the inadequacy of the SBM model to reproduce the low fields data when the 
tumbling motion is so long. The parameters 2 and V were treated simply as fitting 
parameters and do not have a precise physical meaning. The values of q, rGdH, and M 
were assumed to be identical to those found for the parent Gd complex. 
 
The results are consistent with the presence of a slow tumbling motion of the system, 
superimposed on fast local rotation of the Gd-chelates. [19] This is underlined by the 
low value of S
2
. Moreover, the relaxivity reaches a maximum value at 30 MHz 
(typically found at 20 MHz for more ‘rigid’ systems) of 15.9 mM-1s-1 at 310 K. This 
is probably a consequence of a relatively fast internal motion (0.49 ns) rather than the 
slow global rotation (6 ns). The relatively long residence lifetime of the inner sphere 
water molecule limits the relaxivity of the slowly tumbling system. Indeed, the 
relaxivity increases significantly with temperature. A maximum value is reached 
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around 315 K. A simple simulation revealed that the relaxivity would increase to 27 if 
M was 20 ns at 298 K and 20 MHz.  
 
Table 4  Relaxation data for [Gd.L
1
(H2O)-chitosan].
a 
parameter  298 K
 
310 K 
r1p (mM
-1 
s
-1
)
b 
12.7 14.9 
M 
 
(s) 0.92 0.63 
RL (ns) 0.58 0.49 
RG (ns) 8 6 
S
2
 0.09 0.17 
V (ps) 21 20 
2 (s-2   1019) 1.4 1.4 
q 1 1 
a (Å) 4.0 4.0 
D (cm
2
 s
-1
   10-5) 2.24 3.10 
a RG is the global rotation of the whole paramagnetic system; RL the local motion 
contribution; S
2 
the correlation between the global and local motion; a the Gd-H distance 
for the outer sphere water molecules and D the relative diffusion coefficient; 
b
 at 20 MHz 
 
Proton MRI studies with [Gd.L
1
(H2O)-chitosan] 
 
MRI studies with the [Gd.L
1
(H2O)-chitosan] conjugate were performed using nude 
mice bearing an HT29 colorectal tumour xenograft as animal model, with the aim of 
assessing the distribution and the tumour uptake of the conjugate. The mice were 
anaesthetised with a mixture of oxygen/1-2% isoflurane, placed in the MR system and 
scout images obtained. A Dynamic Contrast Enhanced (DCE) MRI study was 
performed in a single 2 mm slice containing the tumour and acquiring a total of 100 
over a 10 min acquisition period.  Five baseline 
1
H MR images were collected (30 s) 
after which 200 l of a 2.5 mM solution of the Gd complex-chitosan conjugate was 
administered by manual intravenous injection in the tail during the sixth image. Each 
mouse (~30 g, n=4) received a dose of 0.017 mmol/kg.  An almost immediate contrast 
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enhancement (<1 min) was observed after administration of the conjugate, both in the 
tumour and the bladder (Fig. 5). The compound was well tolerated by the animals. 
 
  
 
    
Figure  5    T-1 weighted 
1
H MR images : left before and right after 
administration of [Gd.L
1
(H2O)-chitosan] (0.017 mmol/kg dose) in a nude 
mouse bearing an HT-29 colorectal tumour xenograft (arrow).  
 
The tumour area was analyzed to measure the mean signal intensity profile as a 
function of time (Fig. 6). Rapid and selective uptake of the conjugate was observed in 
the tumour, within the 10 min acquisition time. This behaviour is most probably 
related to an EPR effect (enhanced permeability and retention) that is characteristic of 
such medium molecular weight conjugates. [15] This leads to their selective 
accumulation in tumours through the increased fenestration of the blood vessels in the 
area and subsequent slower rates of clearance from the site. This represents a potential  
advantage of such conjugates compared to lower molecular weight Gd complexes, 
which in healthy animals are usually more rapidly excreted via the kidney or liver and 
accumulate in the bladder more quickly after administration.   
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Figure 6  Temporal profile of the mean intensity of the tumour area, 
showing the increase in signal intensity following intravenous 
administration of [Gd.L
1
(H2O)-chitosan] (17 mol/kg); the data shown 
represents the mean intensity value averaged over four animals (±SEM). 
.Fluctuations in the mean signal reflect effects of uncompensated 
respiratory motion; however, the overall long term signal trend is clear. 
 
The presence of conjugate in the bladder and liver is consistent with both renal and 
biliary excretion, indicating that the conjugate is being eliminated from the body by 
each of the major pathways. The increase of the mean signal intensity reached the 
value of 1.22. Corresponding values obtained using the commercially available Gd 
contrast agent Prohance and in analogous experiments were in the range 1.20-1.28, 
although the latter was administered at a higher dose, i.e. 0.1 mmol/kg against 0.017 
mmol/kg for the Gd-chitosan conjugate.  
 
A similar scouting experiment was undertaken with [Gd.L
3
-chitosan] to track its 
uptake, this time examining mice (4) bearing a related HCT-116 colorectal tumour 
xenograft.  Conventional dynamic gradient spin-echo MR scans (6.66 s temporal 
resolution) were taken pre (6 scans) and post-injection, over a 13 minute period 
following a single tail-vein injection of an 0.03mmol/kg dose of the conjugate.  The 
data was analysed in terms of the change in intensity (pre vs post contrast (13 min.) in 
the tumour, kidney, liver, bladder and muscle (Fig. 7).  The changes in intensity for 
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tumour to liver and tumour to muscle at this time point were 2:1 and 5:1 respectively, 
with again clear evidence for predominant renal clearance, with similar retention over 
this time interval in the tumour and liver tissues.   
 
 
   
Figure 7   Change in signal intensity in proton MR images taken 13 minutes 
after tail vein injection of an 0.03mmol/kg dose of [Gd.L
3
-chitosan] 
 
 
 
19
F   MR Imaging studies  
 
A 
19
F MRI dynamic experiment was performed using the [Ho.L
1
(H2O) chitosan] 
conjugate, using a dose of 0.034 mmol/kg on the HT-29 animal model. A similar 
dynamic sequence was used to acquire 
19
F MR images over one hour. No fluorine 
signal was detected after administration of the conjugate, most likely due to the rather 
broad linewidth observed (750 Hz) that led to T2 losses in signal acquisition and 
hence insufficient signal intensity for observation on the experimental timescale.  
Preliminary imaging studies with [Dy.L
3
-chitosan] were carried out using a 3D 
gradient echo sequence (Fig. 8) with a four turn solenoid coil (20 mm diameter, 20 
mm coil length).  The R1 and R2 values were estimated to be 145 and 270 Hz, 
respectively, leading to a calculated Ernst angle of 60.7
o
 for a repetition rate, TR, of 25 
ms. With a total scan duration of 131 s, good quality images were acquired at a 
resolution of 1x1x1 mm
3
.  Shorter echo times, TE (2.07 ms), were applied in order to 
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minimise R2 loss.  The resulting mean signal-to-noise ratio (SNR) from the 1x1x1 
mm
3
 volume element was calculated to be 9.1, which was a significant improvement 
on previously studied compounds when scaled for comparison (to take account of 
differences in total examination time and concentration).  These results were 
promising for further investigation, and in vivo experiments were undertaken. 
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Figure 8 
19
F MR phantom images of [Dy.L
3
-chitosan] contained in an 
Eppendorf tube (2 mM complex, H2O, 0.1 M NaCl, 7 T, 295 K, 3D 
gradient echo sequence, 1x1x1 mm
3
 resolution, TR = 4.91 ms, TE = 
2.07 ms, flip angle = 60.7
o
, 26 averages, scan duration = 131 s, mean 
SNR from 1x1x1 mm
3
 = 9.1). 
 
Preliminary in vivo studies were carried out on SCID male mice (30 g) with HT29 
tumours.  Measurements were taken 10-14 days after inoculation when tumours were 
around 10 mm in diameter, with the mouse anaesthetised with a mixture of ketamine 
(0.75 mg/kg) and medetomidine (0.5-1.0 mg/kg). ).  The animal was positioned on a 
19
F tuned square surface coil (30 mm coil length) and the MR system was calibrated 
using a reference vial placed between the animal and the coil which was subsequently 
removed remotely without disturbing the animal.  A solution (5 mM) of [Dy.L
3
-
chitosan] was then administered by intravenous injection in the tail.  The mouse 
received 250 µL of the solution, corresponding to a dose of 0.037 mmol/kg.  
Immediately following injection simple detection of the [Dy.L
3
-chitosan] was 
confirmed using unlocalised spectroscopy which demonstrated both the expected 
resonance and a second unidentified resonance shifted by -4900Hz (-17ppm), which 
was not seen from the reference sample (Fig.9).  The nature of this second species 
remains uncertain, at present. While the in vitro data (Fig. 8) could be collected using 
a standard imaging sequence, the linewidths in vivo were broader and localised 
spectral detection was therefore employed using a 2D spectroscopic imaging 
approach allowing much shorter TE and hence reduced R2 related signal loss. The 
distribution of the complex within the animal was clearly mapped. 
 
 
 
 
 
 
 
 
Figure 9 In vivo data showing detection of 19F signal from [Dy.L3-chitosan]. Left: stack plot 
of unlocalised post-injection 
19
F spectra (35s hard excitation pulse, flip angle = 90o, 
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sweep width = 40 kHz, TR = 55ms, 2048 averages, scan duration = 113s).  Also 
shown is the signal from a reference vial placed on the coil for pulse calibration. 
Right: representative conventional gradient echo T1 weighted MRI and spectroscopic 
imaging data with effective in-plane voxel size of ~3mm (35ms hard excitation pulse, 
flip angle = 90
o
, sweep width = 40 kHz, TR = 55ms, TE = 0.22 ms, 48 averages, scan 
duration = 169s, in-plane resolution 4x4mm, zero-filled to 2x2mm). Variation in the 
spatial distribution of the resonances at 0 and -4900 Hz are clearly seen in the 
spectroscopic imaging data. Gridlines on the image indicate the equivalent location of 
each spectrum in the MRSI dataset.    
 
 
 
 
Conclusions 
 
This proof-of principle study introduces the idea of a fast-relaxing fluorinated probe 
in a conjugate that clears relatively slowly from the body. These features allow 19-F 
chemical spectral imaging studies to be undertaken at doses that are in the range of 
those used in the clinically approved series of gadolinium contrast agents.  There 
remains a need to understand better the origins of the line-broadening phenomenon 
observed in vivo, as this limits the resolution and sensitivity of the method, with the 
materials examined herein.  A tentative suggestion may be that there is some non-
covalent association in vivo with endogenous macromolecules, e.g. protein that gives 
rise to some chemical exchange broadening.  
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The work has wider implications, as it demonstrates that a fast-relaxing spin label can 
be observed in vivo on timescales that are amenable to modern imaging methods. 
Such behaviour holds, provided that the label can be observed selectively in the 
appropriate spectral window. In the systems described here, the extension to Gd-
enhanced imaging studies of the water signal is particularly useful, as it allows 
genuine dual imaging protocols to be developed, observing water and probe signals 
sequentially, simply be permuting the lanthanide ion in the same ligand or conjugate 
structure.   
 
The extension of these ideas to the use of paramagnetically shifted proton spin labels 
(‘PARASHIFT’ proton MR) is being reported concurrently [20] for related 
macrocyclic structures, labelled with a t-butyl reporter resonance that is around 6 to 7 
Å from the paramagnetic centre.   
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